Latest News

AP VALVES & SH 2022

SAVR always better for younger AS? 'Durability data up to 10-years greenlights TAVR for patients between 65-70'

Long-term valve durability becomes crucial for younger AS populations; intermediate-term data strengthens case for TAVR in select patients under 70 years

AP VALVES & SH 2022

Data on TAVR-related stroke 'not enough, hard to justify routine EPD use except in BAV, ViVs,'

David J. Cohen, MD says field 'just not that good' at predicting TAVR-related stroke and its effects, but EPDs help patients with bicuspid valves, ViV procedures for now

AP VALVES & SH 2022

Not just alternative to SAVR: 'TAVR has become standard of treatment for severe, symptomatic AS'

AMC Heart Institute's Chairman Seung-jung Park, MD, PhD says 'For Tissue Valves, SAVR is Alternative to TAVR' in Severe, Symptomatic AS Patients Over 65 Years

Download

Partner Events